A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Subcutaneous Doses of SAR231893/REGN668 in Healthy Japanese Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2013
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2012 Planned number of patients changed from 24 to 32 as reported by ClinicalTrials.gov.
- 09 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.